Brief: Amylyx Pharmaceuticals Announces Interim Data From Ongoing Mid-Stage Trial Of AMX0035
10/04/2024 14:31
April 10 (Reuters) - Amylyx Pharmaceuticals Inc
AMLX.O :
* AMYLYX PHARMACEUTICALS ANNOUNCES INTERIM DATA FROM ONGOING
PHASE
2 HELIOS CLINICAL TRIAL DEMONSTRATING IMPROVEMENTS IN PANCREATIC
FUNCTION AND GLYCEMIC CONTROL WITH AMX0035 IN PEOPLE WITH
WOLFRAM SYNDROME
* AMYLYX PHARMACEUTICALS INC: AMX0035 WAS GENERALLY
WELL-TOLERATED
IN ALL PARTICIPANTS
* AMYLYX PHARMACEUTICALS INC: MAJORITY OF PARTICIPANTS IN
STUDY
REPORTED SOME IMPROVEMENT IN VISION
* AMYLYX PHARMACEUTICALS INC: EXPECT TOPLINE DATA FOR ALL 12
PARTICIPANTS AT WEEK 24 IN SECOND HALF OF THIS YEAR
Source text for Eikon: ID:nBw35gfb5a
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock